TL-003 vs tulisokibart

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: TL1A · full Ulcerative Colitis pipeline

TL-003

Developed by Bionyra Pharma under a licence from TrueLab Biopharmaceutical

Phase 1 in Ulcerative Colitisbispecific antibody (anti-TL1A/IL-23, extended half-life)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2027 · NCT07526519 (registry estimate)

No aligned efficacy figure on record for this race.

tulisokibart

Developed by Merck & Co.

Phase 3 in Ulcerative Colitismonoclonal antibody (humanized)
Reliable signal

NCT06052059 · Phase 3 · active, not recruiting

First Ph3 induction win for any anti-TL1A; met primary + key secondaries (June 2026).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2037 · NCT06651281 (registry estimate)

Reported efficacy

Clinical remission (MMS) at week 12: ATLAS-UC Study 2 (NCT06052059): tulisokibart met its primary endpoint of clinical remission (Modified Mayo Score) at week 12, plus key secondary endpoints. (met)

Result source: NCT06052059

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointTL-003tulisokibart
Clinical remission (induction)—Not reported26.5% vs 1.5%+25 vs placebowk 12 · n 68NCT04996797
1 other result
  • 31.6% vs 10.8% wk 12 · n 38 · Phase 2 · secondary NCT04996797
Clinical remission (maintenance)—Not reported—Trial running · NCT06052059
Clinical response (induction)—Not reported66.2% vs 22.4%+43.8 vs placebowk 12 · n 68NCT04996797
1 other result
  • 55.3% vs 32.4% wk 12 · n 38 · Phase 2 · secondary NCT04996797
Endoscopic improvement (induction)—Not reported36.8% vs 6%+30.8 vs placebowk 12 · n 68NCT04996797
1 other result
  • 36.8% vs 18.9% wk 12 · n 38 · Phase 2 · secondary NCT04996797
Corticosteroid-free remission (maintenance)—Not reported—Trial running · NCT06052059

Clinical remission (induction)

TL-003
—Not reported
tulisokibart
26.5% vs 1.5%+25 vs placebowk 12 · n 68NCT04996797
1 other result
  • 31.6% vs 10.8% wk 12 · n 38 · Phase 2 · secondary NCT04996797

Clinical remission (maintenance)

TL-003
—Not reported
tulisokibart
—Trial running · NCT06052059

Clinical response (induction)

TL-003
—Not reported
tulisokibart
66.2% vs 22.4%+43.8 vs placebowk 12 · n 68NCT04996797
1 other result
  • 55.3% vs 32.4% wk 12 · n 38 · Phase 2 · secondary NCT04996797

Endoscopic improvement (induction)

TL-003
—Not reported
tulisokibart
36.8% vs 6%+30.8 vs placebowk 12 · n 68NCT04996797
1 other result
  • 36.8% vs 18.9% wk 12 · n 38 · Phase 2 · secondary NCT04996797

Corticosteroid-free remission (maintenance)

TL-003
—Not reported
tulisokibart
—Trial running · NCT06052059
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

TL-003: no structured comparison results are available for Ulcerative Colitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. TL-003: 0 of 4 rows · tulisokibart: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metrictulisokibart
Dropout rate
—All Cohorts (Cohort 1 & Cohort 2)
NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2
show 1 more result
n/a: no completion milestoneCohort 1 Tulisokibart
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Discontinued due to AEs
—All Cohorts (Cohort 1 & Cohort 2)
NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2
show 1 more result
0%Cohort 1 Tulisokibart
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Serious AEs
1.1%All Cohorts (Cohort 1 & Cohort 2)
NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2
show 1 more result
—Cohort 1 Tulisokibart
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
Most frequent reported AEs
covid-19 5.6% (placebo 4.5%)
NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

tulisokibart

Clinical Remission 26.5% (n=68) vs 1.5% (n=67) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
31.6% (n=38) vs 10.8% (n=37) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Endoscopic Improvement 36.8% (n=68) vs 6% (n=67) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
36.8% (n=38) vs 18.9% (n=37) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Clinical Response 66.2% (n=68) vs 22.4% (n=67) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
55.3% (n=38) vs 32.4% (n=37) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Symptomatic Remission 19.1% (n=68) vs 6% (n=67) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
21.1% (n=38) vs 10.8% (n=37) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Histologic Improvement 46.2% (n=65) vs 17.5% (n=57) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
55.6% (n=36) vs 26.7% (n=30) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Histologic-Endoscopic Mucosal Improvement 30.8% (n=65) vs 3.5% (n=57) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
38.9% (n=36) vs 16.7% (n=30) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
Histologic-endoscopic Mucosal Healing 30.8% (n=65) vs 3.5% (n=57) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
38.9% (n=36) vs 16.7% (n=30) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2
IBDQ 82.4% (n=68) vs 49.3% (n=67) placebo @ 12wk
responder rate · % of participants
NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2
show 1 more result
76.3% (n=38) vs 56.8% (n=37) placebo @ 12wk
NCT04996797 · Phase 2 · combination · Ulcerative Colitis · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: TL-003's landscape · tulisokibart's landscape